AVXL
Anavex Life Sciences Corporation
-22.55%
$11.75 - $9.10
Feb 7th 2023 - Mar 21st 2023
Mar, 6, 2023
$AVXL thanks yet again Bill.
Dec, 9, 2022
Worth the risk with patience and not investing lif... See more
No reviews available.
No reviews available.
Mar, 6, 2023
$AVXL thanks yet again Bill.
Dec, 9, 2022
Worth the risk with patience and not investing lifestyle or bill money.
Dec, 9, 2022
But, after cognition tests the trial passed all endpoints!
Dec, 9, 2022
THEN they said it hadnt passed any trials, well gee whiz now met BOTH secondary Endpoints. Newsflash.
Dec, 9, 2022
Blarcamesine passed every endpoints. .
Dec, 7, 2022
Key is we passed all endpoints with statically significant results!
Dec, 7, 2022
Hahah .. passed easily!
Dec, 3, 2022
Passed it all no problem!
Oct, 20, 2022
After TLR, Anavex will be the owner of a first-in-class, patented, medically-proven, high-demand asset that merely needs to pass through the technicality of government approval to qualify it for mass marketing.